Literature DB >> 21488085

Spatial and temporal changes in promoter activity of the astrocyte glutamate transporter GLT1 following traumatic spinal cord injury.

Angelo C Lepore1, John O'Donnell, Joseph F Bonner, Courtney Paul, Mark E Miller, Britta Rauck, Robert A Kushner, Jeffrey D Rothstein, Itzhak Fischer, Nicholas J Maragakis.   

Abstract

After traumatic spinal cord injury (SCI), there is an opportunity for preserving function by attenuating secondary cell loss. Astrocytes play crucial roles in the adult CNS and are responsible for the vast majority of glutamate buffering, potentially preventing excitotoxic loss of neurons and oligodendrocytes. We examined spatial and temporal changes in gene expression of the major astrocyte glutamate transporter GLT1 following moderate thoracic contusion SCI using transgenic BAC-GLT1-eGFP promoter reporter mice. In dorsal column white matter, total intensity of GLT1-eGFP expression per region was significantly reduced following SCI at both lesion epicenter and at rostral and caudal areas where no tissue loss occurred. This regional decrease in GLT1 expression was due to significant loss of GLT1-eGFP(+) cells, partially accounted for by apoptosis of eGFP(+) /GFAP(+) astrocytes in both white and gray matter. There were also decreased numbers of GLT1-eGFP-expressing cells in multiple gray matter regions following injury; nevertheless, there was sustained or even increased regional GLT1-eGFP expression in gray matter as a result of up-regulation in astrocytes that continued to express GLT1-eGFP. Although there were increased numbers of GFAP(+) cells both at the lesion site and in surrounding intact spinal cord following SCI, the majority of proliferating Ki67(+) /GFAP(+) astrocytes did not express GLT1-eGFP. These findings demonstrate that spatial and temporal alterations in GLT1 expression observed after SCI result from both astrocyte death and gene expression changes in surviving astrocytes. Results also suggest that following SCI a significant portion of astrocytes lacks GLT1 expression, possibly compromising the important role of astrocytes in glutamate homeostasis.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21488085      PMCID: PMC9162082          DOI: 10.1002/jnr.22624

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.433


  48 in total

1.  Administration of glutamate into the spinal cord at extracellular concentrations reached post-injury causes functional impairments.

Authors:  Guo-Ying Xu; Michael G Hughes; Liping Zhang; Lisa Cain; David J McAdoo
Journal:  Neurosci Lett       Date:  2005-08-26       Impact factor: 3.046

2.  Transplantation of neuronal and glial restricted precursors into contused spinal cord improves bladder and motor functions, decreases thermal hypersensitivity, and modifies intraspinal circuitry.

Authors:  Takahiko Mitsui; Jed S Shumsky; Angelo C Lepore; Marion Murray; Itzhak Fischer
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

3.  MR imaging of lineage-restricted neural precursors following transplantation into the adult spinal cord.

Authors:  A C Lepore; P Walczak; M S Rao; I Fischer; J W M Bulte
Journal:  Exp Neurol       Date:  2006-06-09       Impact factor: 5.330

4.  Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats.

Authors:  M Gaviria; A Privat; P d'Arbigny; J Kamenka; H Haton; F Ohanna
Journal:  Brain Res       Date:  2000-08-25       Impact factor: 3.252

5.  Dose-dependent reduction of tissue loss and functional impairment after spinal cord trauma with the AMPA/kainate antagonist NBQX.

Authors:  J R Wrathall; D Choiniere; Y D Teng
Journal:  J Neurosci       Date:  1994-11       Impact factor: 6.167

6.  NBQX treatment improves mitochondrial function and reduces oxidative events after spinal cord injury.

Authors:  Xiaojun Mu; Robert D Azbill; Joe E Springer
Journal:  J Neurotrauma       Date:  2002-08       Impact factor: 5.269

7.  Gliopathy ensures persistent inflammation and chronic pain after spinal cord injury.

Authors:  Claire E Hulsebosch
Journal:  Exp Neurol       Date:  2008-07-29       Impact factor: 5.330

Review 8.  Glutamate transporters: animal models to neurologic disease.

Authors:  Nicholas J Maragakis; Jeffrey D Rothstein
Journal:  Neurobiol Dis       Date:  2004-04       Impact factor: 5.996

9.  Reactive astrocytes protect tissue and preserve function after spinal cord injury.

Authors:  Jill R Faulkner; Julia E Herrmann; Michael J Woo; Keith E Tansey; Ngan B Doan; Michael V Sofroniew
Journal:  J Neurosci       Date:  2004-03-03       Impact factor: 6.167

Review 10.  Mechanisms of chronic central neuropathic pain after spinal cord injury.

Authors:  Claire E Hulsebosch; Bryan C Hains; Eric D Crown; Susan M Carlton
Journal:  Brain Res Rev       Date:  2008-12-25
View more
  18 in total

1.  Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury.

Authors:  Angelo C Lepore; John O'Donnell; Andrew S Kim; Eun Ju Yang; Alisha Tuteja; Amanda Haidet-Phillips; Colin P O'Banion; Nicholas J Maragakis
Journal:  Glia       Date:  2011-08-31       Impact factor: 7.452

Review 2.  Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury.

Authors:  Charles Nicaise; Dinko Mitrecic; Aditi Falnikar; Angelo C Lepore
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 3.  Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats.

Authors:  Young S Gwak; Jonghoon Kang; Geda C Unabia; Claire E Hulsebosch
Journal:  Exp Neurol       Date:  2011-10-21       Impact factor: 5.330

Review 4.  Harnessing the power of cell transplantation to target respiratory dysfunction following spinal cord injury.

Authors:  Brittany A Charsar; Mark W Urban; Angelo C Lepore
Journal:  Exp Neurol       Date:  2016-08-13       Impact factor: 5.330

5.  Human iPS cell-derived astrocyte transplants preserve respiratory function after spinal cord injury.

Authors:  Ke Li; Elham Javed; Daniel Scura; Tamara J Hala; Suneil Seetharam; Aditi Falnikar; Jean-Philippe Richard; Ashley Chorath; Nicholas J Maragakis; Megan C Wright; Angelo C Lepore
Journal:  Exp Neurol       Date:  2015-07-26       Impact factor: 5.330

6.  Overexpression of the astrocyte glutamate transporter GLT1 exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb motor dysfunction following cervical contusion spinal cord injury.

Authors:  Ke Li; Charles Nicaise; Daniel Sannie; Tamara J Hala; Elham Javed; Jessica L Parker; Rajarshi Putatunda; Kathleen A Regan; Valérie Suain; Jean-Pierre Brion; Fred Rhoderick; Megan C Wright; David J Poulsen; Angelo C Lepore
Journal:  J Neurosci       Date:  2014-05-28       Impact factor: 6.167

Review 7.  "Targeting astrocytes in CNS injury and disease: A translational research approach".

Authors:  Angela R Filous; Jerry Silver
Journal:  Prog Neurobiol       Date:  2016-03-26       Impact factor: 11.685

Review 8.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

9.  Chronic at-level thermal hyperalgesia following rat cervical contusion spinal cord injury is accompanied by neuronal and astrocyte activation and loss of the astrocyte glutamate transporter, GLT1, in superficial dorsal horn.

Authors:  Rajarshi Putatunda; Tamara J Hala; Jeannie Chin; Angelo C Lepore
Journal:  Brain Res       Date:  2014-05-14       Impact factor: 3.252

10.  In vivo microdialysis of glutamate in ventroposterolateral nucleus of thalamus following electrolytic lesion of spinothalamic tract in rats.

Authors:  A Ghanbari; A R Asgari; G R Kaka; H R Falahatpishe; A Naderi; M Jorjani
Journal:  Exp Brain Res       Date:  2013-11-02       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.